MG-63 Transfection Kit (Osteosarcoma, CRL-1427)

Description

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Transfection Reagent for MG-63 Cells (Osteosarcoma Cells, CRL-1427)

• Two component formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• High transfection efficacy in the presence of serum
• Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
• Reproducible transfection results
• Works well for standard reverse transfection and high-throughput applications
• Download in vitro MG63 transfection protocol: [PDF]
• Download MG63 CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for NIH3T3 transfection kit: [PPT]
• UPC/GTIN/EAN: 860002089789
• Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 77% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

This transfection kit is specially designed for the MG63 cell line, a human osteosarcoma cells. It ensures high efficiency in delivering both DNA and RNA into these cells.

Transfection Protocol and SDS:

Download Altogen Biosystems MG-63 Transfection Protocol: [PDF]

Download SDS: [PDF]

MG-63 Cell Line:

MG63 cells are a human osteosarcoma cell line that was originally isolated from a 14-year-old patient with osteoblastic osteosarcoma. These cells are widely used as an in vitro model of bone cancer to study the mechanisms underlying tumor development and to test the efficacy of potential therapeutic agents. MG63 cells exhibit many of the characteristics of osteosarcoma cells, including the ability to form colonies in vitro and to form tumors when injected into immunocompromised mice. MG-63 cells have been used to study the role of various signaling pathways in osteosarcoma, including the PI3K/Akt, MAPK/ERK, and Wnt/β-catenin pathways. These pathways are known to be dysregulated in many types of cancer, including osteosarcoma, and targeting them with therapeutic agents has shown promise in preclinical studies. MG63 cells have also been used to test the efficacy of various chemotherapeutic agents, including doxorubicin, cisplatin, and methotrexate. In addition, these cells have been used to develop and test novel targeted therapies, such as monoclonal antibodies and small molecule inhibitors.

Sarcoma is a cancer of bones and connective tissues that is quite rare in adults. However, it comprises approximately 20% of all childhood cancers, as indicated by the Sarcoma Foundation of America (SFA). Human cell lines are valuable preclinical models for sarcoma research as well as for evaluation of the efficacy or toxicity of potential drug candidates. The MG-63 cell line was established from the bone tissue of a 14-year-old Caucasian male with osteosarcoma. This cell line exhibits fibroblast morphology and shows high levels of interferon production when induced by cycloheximide, actinomycin D, and polyinosinic-polycytidylic acid. These MG-63 cells express TGF-beta RI and TGF-beta RII receptors and could be useful as a transfection host in different types of biomedical research applications. The MG-63 cell line is hypotriploid with a modal chromosome number of 66. Altogen Biosystems provides high-efficiency transfection reagent kits for the MG-63 osteosarcoma cell line.

Mutations:

Data:

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into MG63 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

Figure 2. Protein expression of Lamin A in MG-63 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into MG-63 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

MG63 Transfection Reagent citation references:

• Data Brief. 2016 Jun; 7: 177–182. Data supporting attempted caveolae-mediated phagocytosis of surface-fixed micro-pillars by human osteoblasts. Moerke et al [PDF]

Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection  efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6848)
• 1.5 ml (Catalog #6849)
• 1.5 ml CRISPR (Catalog #2173)
• 8.0 ml (Catalog #7063)

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.